Noticias de ATOS_US

Noticias del mercado

Últimas noticias sobre ATOS_US — 117 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATOS_US ✕ 117 resultados
04/05/2026 ATOS_US — Investing.com
Atossa Genetics stock surges after FDA rare disease designation
28/04/2026 ATOS_US — MSN
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46
28/04/2026 ATOS_US — MSN
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46
27/04/2026 ATOS_US — ChartMill
ATOS Forecast, Price Target & Analyst Ratings | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS)
26/04/2026 ATOS_US — MSN ES ← EN
Las acciones de ATOS caen un 32%: esto es lo que piensan los inversores minoristas sobre la división inversa de acciones

ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split

25/04/2026 ATOS_US — Aktiellt ES ← EN
Atossa Therapeutics informa los resultados financieros del cuarto trimestre y de fin de año 2025 y proporciona una actualización corporativa

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

24/04/2026 ATOS_US — Traders Union ES ← EN
Atossa Therapeutics se une a los líderes de la industria en LSINW2026 para impulsar el impulso de innovación en terapia celular

Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum

23/04/2026 ATOS_US — MSN
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split
17/04/2026 ATOS_US — ChartMill
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS)
16/04/2026 ATOS_US — Investing.com ES ← EN
Atossa Therapeutics llega a un acuerdo en la disputa sobre la patente del endoxifeno Por Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute
16/04/2026 ATOS_US — TipRanks
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
14/04/2026 ATOS_US — Traders Union
Atossa Therapeutics advances endoxifen as new option for DMD management
13/04/2026 ATOS_US — MSN ES ← EN
El precio objetivo de Atossa Therapeutics (ATOS) disminuyó un 31,37% a 44,62
10/04/2026 ATOS_US — MSN
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62
10/04/2026 ATOS_US — GuruFocus
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News

Página 4 de 6

keyboard_arrow_up